{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T02:12:01.353827+00:00","company":{"ticker":"PACB","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC."},"pagination":{"limit":100,"returned":18,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"c2e13a5d771550210e6c7263b1f2747b9a004431","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-06-04T21:19:08+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-03","outcome":"passed","proposal_text":"Approval of Amendment to the 2020 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"65,778,311","subject":null,"votes_abstain":"1,896,112","votes_against":"20,469,132","votes_for":"114,865,820","votes_withheld":null}]},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Approval of Amendment to the 2020 Equity Incentive Plan at the 2026-06-03 meeting.","evidence_excerpt":"Proposal 4: Approval of Amendment to the 2020 Equity Incentive Plan For Against Abstain Broker Non-Votes 114,865,820 20,469,132 1,896,112 65,778,311 The stockholders approved the amendment to the 2020 Plan","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001299130-26-000092","anchor_url":"https://secwatch.observer/filing/0001299130-26-000092#claim-c2e13a5d771550210e6c7263b1f2747b9a004431","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000092/0001299130-26-000092-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b8772152e7e0f9c57469b1465b31299f13ce59f1","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-06-04T21:19:08+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-03","outcome":"passed","proposal_text":"Advisory Vote on Approval of Named Executive Officer Compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"65,778,311","subject":null,"votes_abstain":"1,940,145","votes_against":"21,239,989","votes_for":"114,050,930","votes_withheld":null}]},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Advisory Vote on Approval of Named Executive Officer Compensation at the 2026-06-03 meeting.","evidence_excerpt":"Proposal 3: Advisory Vote on Approval of Named Executive Officer Compensation For Against Abstain Broker Non-Votes 114,050,930 21,239,989 1,940,145 65,778,311 The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001299130-26-000092","anchor_url":"https://secwatch.observer/filing/0001299130-26-000092#claim-b8772152e7e0f9c57469b1465b31299f13ce59f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000092/0001299130-26-000092-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4d8c66b0b9c9e7edcc17c32aa60917617d67fb29","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-06-04T21:19:08+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-03","outcome":"passed","proposal_text":"Ratification of the Appointment of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"972,226","votes_against":"3,990,483","votes_for":"198,046,666","votes_withheld":null}]},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-03 meeting.","evidence_excerpt":"Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 198,046,666 3,990,483 972,226 — The stockholders ratified the appointment of Ernst & Young LLP","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001299130-26-000092","anchor_url":"https://secwatch.observer/filing/0001299130-26-000092#claim-4d8c66b0b9c9e7edcc17c32aa60917617d67fb29","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000092/0001299130-26-000092-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4a204815f84109961cefa5faccfb77c6a3301a26","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-06-04T21:19:08+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-03","outcome":"passed","proposal_text":"Election of Four Class III Directors","proposal_type":"director_election","results":[{"broker_non_votes":"65,778,311","subject":"William Ericson","votes_abstain":"1,111,140","votes_against":null,"votes_for":"128,010,323","votes_withheld":null},{"broker_non_votes":"65,778,311","subject":"Kathy Ordoñez","votes_abstain":"1,034,848","votes_against":null,"votes_for":"130,522,400","votes_withheld":null},{"broker_non_votes":"65,778,311","subject":"Christopher M. Smith","votes_abstain":"1,430,492","votes_against":null,"votes_for":"131,731,235","votes_withheld":null},{"broker_non_votes":"65,778,311","subject":"Chris Gibson, Ph.D.","votes_abstain":"1,224,044","votes_against":null,"votes_for":"131,899,750","votes_withheld":null},{"broker_non_votes":"65,778,311","subject":"Christian O. Henry","votes_abstain":"1,307,031","votes_against":null,"votes_for":"129,999,918","votes_withheld":null},{"broker_non_votes":"65,778,311","subject":"John F. Milligan, Ph.D.","votes_abstain":"1,108,523","votes_against":null,"votes_for":"130,471,635","votes_withheld":null}]},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. shareholders approved Election of Four Class III Directors at the 2026-06-03 meeting.","evidence_excerpt":"Proposal 1: Election of Four Class III Directors Name of Director For Against Abstain Broker Non-Votes William Ericson 128,010,323 8,109,601 1,111,140 65,778,311 Kathy Ordoñez 130,522,400 5,673,816 1,034,848 65,778,311 Christopher M. Smith 131,731,235 4,069,337 1,430,492 65,778,311 Chris Gibson, Ph.D. 131,899,750 4,107,270 1,224,044 65,778,311 Christian O. Henry 129,999,918 5,924,115 1,307,031 65,778,311 John F. Milligan, Ph.D. 130,471,635 5,650,906 1,108,523 65,778,311 Each director nominee was duly elected","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001299130-26-000092","anchor_url":"https://secwatch.observer/filing/0001299130-26-000092#claim-4a204815f84109961cefa5faccfb77c6a3301a26","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000092/0001299130-26-000092-index.htm"},{"fact_type":"earnings_release","fact_key":"0fed28391e9de8bae055fa7b375a766864e5feaf","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"GAAP net loss per share for the first quarter of 2026 was $0.03","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"GAAP net loss for the first quarter of 2026 was $8.3 million","period_text":"for its first fiscal quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$37.2"},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported for its first fiscal quarter ended March 31, 2026 results: revenue $37.2, net income GAAP net loss for the first quarter of 2026 was $8.3 million, EPS GAAP net loss per share for the first quarter of 2026 was $0.03. Guidance reaffirmed.","evidence_excerpt":"which has the potential to produce the largest and most diverse high-fidelity metagenomic dataset in the world.\" First quarter results: Q1 2026 Q1 2025 Revenue (in millions) $37.2 $37.2 Consumable revenue (in millions) $21.8 $20.1 Instrument revenue (in millions) $9.7 $11.0 Service and other revenue (in millions) $5.6 $6.0 Revio TM system placements 15 12","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001299130-26-000076","anchor_url":"https://secwatch.observer/filing/0001299130-26-000076#claim-0fed28391e9de8bae055fa7b375a766864e5feaf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000076/0001299130-26-000076-index.htm"},{"fact_type":"ma_transaction","fact_key":"6d2550be8d109b47446a9226c7a1fbab0da8ed11","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-02-02T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2026-01-30","consideration_text":"$50.0 million in cash","counterparty":"Illumina Cambridge Limited","effective_date":"2026-01-30","item_codes_triggered":["2.01"]},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. completed a disposition involving Illumina Cambridge Limited for $50.0 million in cash (closed 2026-01-30).","evidence_excerpt":"On January 30, 2026, Pacific Biosciences of California, Inc. (the “Company”) completed the disposition of assets to Illumina Cambridge Limited (the “Buyer”) in accordance with the terms of an Asset Purchase Agreement, dated January 30, 2026 (the “Asset Purchase Agreement”), by and between the Company, the Buyer, and Illumina, Inc., solely for purposes of Section 8.16 of the Asset Purchase Agreement, pursuant to which, among other matters, the Buyer acquired certain intellectual property and other assets related to the Company’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies (the “Asset Sale”). As consideration for the Asset Sale, the Buyer paid the Company $50.0 million in cash and assumed certain liabilities (the “Purchase Price”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-009014","anchor_url":"https://secwatch.observer/filing/0001104659-26-009014#claim-6d2550be8d109b47446a9226c7a1fbab0da8ed11","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465926009014/0001104659-26-009014-index.htm"},{"fact_type":"executive_change","fact_key":"806f313017","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2025-03-27T23:59:59+00:00","payload":{"action":"ceases serving as interim CFO","action_category":"role_change","departure_tone":"routine","effective_date":"2025-03-31","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Jim R. Gibson","successor_named":true},"claim":"Christian Henry changed role as President and Chief Executive Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..","evidence_excerpt":"Christian Henry, the Company’s President and Chief Executive Officer, who has been serving also as the Company’s interim Chief Financial Officer and principal financial officer since December 6, 2024 will cease serving as interim Chief Financial Officer and principal financial officer upon commencement of Mr. Gibson’s employment but will continue serving as the Company’s President and Chief Executive officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001299130-25-000072","anchor_url":"https://secwatch.observer/filing/0001299130-25-000072#claim-806f313017","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913025000072/0001299130-25-000072-index.htm"},{"fact_type":"executive_change","fact_key":"5c2bc876c9","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2025-03-27T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jim R. Gibson was appointed as Chief Financial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..","evidence_excerpt":"On March 24, 2025, Pacific Biosciences of California, Inc. (the “Company”) entered into an offer letter with Jim R. Gibson to serve as its Chief Financial Officer. Mr. Gibson will be appointed as the Company’s Chief Financial Officer and principal financial officer effective as of as his first date of employment, which is anticipated to be March 31, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001299130-25-000072","anchor_url":"https://secwatch.observer/filing/0001299130-25-000072#claim-5c2bc876c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913025000072/0001299130-25-000072-index.htm"},{"fact_type":"executive_change","fact_key":"4efd109b68","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2025-01-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-01-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Meline resigned as Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..","evidence_excerpt":"David Meline, a member of the Board, notified the Company of his resignation from the Board, effective January 30, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001299130-25-000015","anchor_url":"https://secwatch.observer/filing/0001299130-25-000015#claim-4efd109b68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913025000015/0001299130-25-000015-index.htm"},{"fact_type":"executive_change","fact_key":"0fd64b22d3","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2025-01-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-30","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christopher M. Smith was appointed as Class III Director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..","evidence_excerpt":"appointed Christopher M. Smith to serve as a Class III director effective January 30, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001299130-25-000015","anchor_url":"https://secwatch.observer/filing/0001299130-25-000015#claim-0fd64b22d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913025000015/0001299130-25-000015-index.htm"},{"fact_type":"executive_change","fact_key":"f958845aea","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-15","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jeff Eidel departed as Chief Commercial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..","evidence_excerpt":"On November 11, 2024, Pacific Biosciences of California, Inc. (the “Company”) notified Jeff Eidel that, in connection with an internal restructuring of the commercial organization, he would separate from his position as the Chief Commercial Officer on November 15, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001299130-24-000185","anchor_url":"https://secwatch.observer/filing/0001299130-24-000185#claim-f958845aea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000185/0001299130-24-000185-index.htm"},{"fact_type":"executive_change","fact_key":"f12630a1a8","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-11-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-12-06","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Susan Kim resigned as Chief Financial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..","evidence_excerpt":"On November 5, 2024, Susan Kim notified the Company that she is voluntarily resigning as Chief Financial Officer of the Company effective on December 6, 2024, to accept a position at another organization.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-115295","anchor_url":"https://secwatch.observer/filing/0001104659-24-115295#claim-f12630a1a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924115295/0001104659-24-115295-index.htm"},{"fact_type":"earnings_release","fact_key":"baa4da2bc0cd0ed9b17deaa70219e6e33b307930","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"end of 2024","report_date":"2024-05-09","result_type":"guidance_update","revenue_text":null},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. updated its end of 2024 guidance (raised).","evidence_excerpt":"Initiated activities to reduce annualized run-rate operating expenses and the Company expects to achieve above the high end of our previously provided range of non-GAAP reduction of $50 million to $75 million by the end of 2024 compared to our prior guidance of 5% operating expense growth.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001299130-24-000109","anchor_url":"https://secwatch.observer/filing/0001299130-24-000109#claim-baa4da2bc0cd0ed9b17deaa70219e6e33b307930","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000109/0001299130-24-000109-index.htm"},{"fact_type":"earnings_release","fact_key":"0abb014caa02057dc8c6e653900bbc498b390738","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"Net loss per share for the first quarter of 2024 was $0.29, compared to net loss per share of $0.36 for the first quarte","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the first quarter of 2024 was $78.2 million, compared to a net loss of $88.0 million for the first quarter","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $78.2 million, compared to a net loss of $88.0 million for the first quarter, EPS Net loss per share for the first quarter of 2024 was $0.29, compared to net loss per share of $0.36 for the first quarte.","evidence_excerpt":"Revenue of $38.8 million compared with $38.9 million in the prior-year period.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001299130-24-000109","anchor_url":"https://secwatch.observer/filing/0001299130-24-000109#claim-0abb014caa02057dc8c6e653900bbc498b390738","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000109/0001299130-24-000109-index.htm"},{"fact_type":"earnings_release","fact_key":"7dd8571e11da4e24888c72e3bb0d2271367f3c8e","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"2024","report_date":"2024-04-16","result_type":"guidance_update","revenue_text":"$170 million to $200 million"},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported 2024 results: revenue $170 million to $200 million. Guidance lowered.","evidence_excerpt":"PacBio now expects 2024 revenue to be in the range of $170 million to $200 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-047511","anchor_url":"https://secwatch.observer/filing/0001104659-24-047511#claim-7dd8571e11da4e24888c72e3bb0d2271367f3c8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm"},{"fact_type":"earnings_release","fact_key":"6aae0ee207fdf9f7ed8636404fb93df5727a79ee","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"lowered","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-04-16","result_type":"preliminary_results","revenue_text":"$38.8 million"},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended March 31, 2024 results: revenue $38.8 million. Guidance lowered.","evidence_excerpt":"– PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results · Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million\nin the prior-year period. · Instrument revenue of $19.0 million compared with $20.7 million in the prior-year\nperiod. · Consumables","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-047511","anchor_url":"https://secwatch.observer/filing/0001104659-24-047511#claim-6aae0ee207fdf9f7ed8636404fb93df5727a79ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465924047511/0001104659-24-047511-index.htm"},{"fact_type":"earnings_release","fact_key":"915d165e558d39605a44c5e66ba1c03b18053768","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"eps_text":"Net loss per share for 2023 was $1.21","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for 2023 was $306.7 million","period_text":"fiscal year ended December 31, 2023","report_date":"2024-02-15","result_type":"reported_results","revenue_text":"Revenue of $200.5 million"},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fiscal year ended December 31, 2023 results: revenue Revenue of $200.5 million, net income Net loss for 2023 was $306.7 million, EPS Net loss per share for 2023 was $1.21.","evidence_excerpt":"Fiscal year 2023 results • Revenue of $200.5 million, a 56% increase compared with $128.3 million in the prior-year period. • Instrument revenue of $120.5 million compared with $48.7 million in the prior-year period. • Consumables revenue of $63.4 million compared with $60.0 million in the prior-year period. • Service and other revenue of $16.6 million compared with $19.6 million in the prior-year period. Gross profit for 2023 was $52.8 million, representing an 8% increase compared with $49.0 million for 2022 and a gross margin of 26% in 2023 compared to 38% for 2022. Non-GAAP gross profit for 2023 was $54.9 million and represented a non-GAAP gross margin of 27% in 2023, compared to a non-GAAP gross profit of $49.8 million in 2022, which represented a non-GAAP gross margin of 39% (see accompanying tables for reconciliations of GAAP and non-GAAP measures). Operating expenses totaled $387.2 million for 2023, compared to $356.2 million for 2022. Non-GAAP operating expenses totaled $354.8","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001299130-24-000014","anchor_url":"https://secwatch.observer/filing/0001299130-24-000014#claim-915d165e558d39605a44c5e66ba1c03b18053768","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000014/0001299130-24-000014-index.htm"},{"fact_type":"earnings_release","fact_key":"db51107ffc354cb57d763966468c0001193ee146","cik":1299130,"ticker":"PACB","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-02-15T23:59:59+00:00","payload":{"eps_text":"Net loss per share for the fourth quarter of 2023 was $0.31","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the fourth quarter of 2023 was $82.0 million","period_text":"fourth fiscal quarter ended December 31, 2023","report_date":"2024-02-15","result_type":"reported_results","revenue_text":"Revenue of $58.4 million"},"claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported fourth fiscal quarter ended December 31, 2023 results: revenue Revenue of $58.4 million, net income Net loss for the fourth quarter of 2023 was $82.0 million, EPS Net loss per share for the fourth quarter of 2023 was $0.31.","evidence_excerpt":"Fourth quarter results • Revenue of $58.4 million, a 113% increase compared with $27.4 million in the prior-year period. • Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. • Consumables revenue of $18.9 million compared with $16.7 million in the prior-year period. • Service and other revenue of $4.4 million compared with $4.6 million in the prior-year period. • Shipped 44 Revio TM sequencing systems in the fourth quarter of 2023, bringing the installed base as of December 31, 2023, to 173 systems. Gross profit for the fourth quarter of 2023 was $9.6 million, representing an 86% increase compared with $5.1 million for the fourth quarter of 2022 and a gross margin of 16% in the fourth quarter of 2023 compared to 19% for the fourth quarter of 2022. Non-GAAP gross profit for the fourth quarter of 2023 was $11.1 million and represented a non-GAAP gross margin of 19% in the fourth quarter of 2023, compared to a non-GAAP gross profit of $5.3 million in","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001299130-24-000014","anchor_url":"https://secwatch.observer/filing/0001299130-24-000014#claim-db51107ffc354cb57d763966468c0001193ee146","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000014/0001299130-24-000014-index.htm"}]}